Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 570,300 shares, a growth of 70.1% from the May 31st total of 335,300 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 0.5 days.
Analyst Upgrades and Downgrades
Separately, Maxim Group started coverage on shares of Virios Therapeutics in a report on Thursday, June 20th. They issued a “buy” rating and a $1.00 price target for the company.
View Our Latest Analysis on Virios Therapeutics
Virios Therapeutics Price Performance
Virios Therapeutics (NASDAQ:VIRI – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. As a group, research analysts forecast that Virios Therapeutics will post -0.27 earnings per share for the current fiscal year.
About Virios Therapeutics
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
See Also
- Five stocks we like better than Virios Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Best Stocks Under $10.00
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the Dow Jones Industrial Average (DJIA)?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.